Less Ads, More Data, More Tools Register for FREE

Pin to quick picksChemring Regulatory News (CHG)

Share Price Information for Chemring (CHG)

Share Price is delayed by 15 minutes
Get Live Data
492.40    -7.00 (-1.40%)
Bid:
493.00
Ask:
493.60
Spread: 0.60 (0.122%)
Market Cap: £1.33b
CHG Live PriceLast checked at - London Stock Exchange

Intraday Chemring Share Chart

Directorate Change

24 Jun 2014 07:00

RNS Number : 3280K
Chemring Group PLC
24 June 2014
 



 FOR IMMEDIATE RELEASE 24 JUNE 2014

 

CHEMRING GROUP PLC

 

Directorate change

 

Michael Flowers appointed Group Chief Executive

 

Chemring Group PLC ("Chemring" or "the Group") announces that Michael Flowers has been appointed Group Chief Executive with immediate effect. Michael joined Chemring in 2006 and prior to today's appointment was Group Director, Countermeasures and a member of Chemring's Executive Committee.

 

Michael Flowers has spent 13 years in senior management positions within the defence industry. He previously served as an officer in the Australian Army for 22 years and was a graduate of the Australian Command and Staff College and the British Royal Military College of Science. After leaving the army, he was a senior manager at BAE Systems from 2001 to 2006, in programme and project management roles.

 

From 2006, he was Managing Director, Chemring Australia, where he established a state of the art countermeasures manufacturing facility and delivered substantial growth in the defence portfolio. In 2013, he was appointed Group Director, Munitions, with responsibility for Chemring's European munitions business. Michael led the successful sale of the European munitions business following the 2013 strategic review, working closely with Chemring's Board and advisers to negotiate and complete the disposal in May 2014.

 

Mark Papworth has stepped down from the Board of Chemring with immediate effect. 

 

Peter Hickson, Chairman of Chemring, said:

 

"Michael Flowers has a proven track record, both within the international defence industry and within Chemring, where he led our Australian business through a successful period of growth and, more recently, managed the complex disposal process of the European munitions business. Michael is extremely knowledgeable about our markets and is well qualified to lead Chemring as we capitalise on our world leading technologies in Countermeasures, Sensors & Electronics and Energetic Systems.

 

Much has been achieved during Mark Papworth's tenure, including a significant reorganisation and refocusing of the Group and a substantial reduction in the cost base and we are grateful for his leadership during this period.

 

We are now moving from a period of critical and significant change to one where we must take maximum advantage of the stronger platform that has been created. To achieve this, a different set of skills is required in the role of Chief Executive, in particular extensive knowledge and understanding of the defence markets in which we operate."

 

Michael Flowers has a beneficial shareholding of 80,680 Chemring shares.

 

There is no further information to be disclosed pursuant to paragraph 9.6.13R of the UK Listing Rules in relation to Michael Flowers' appointment as a director of Chemring.

 

Ends

 

 

 

 

For further information, contact:

 

Chemring Group PLC 01489 881 880

Peter Hickson, Chairman

Steve Bowers, Finance Director

Rupert Pittman, Group Director of Communications and Investor Relations

 

MHP Communications 020 3128 8100

Andrew Jaques

John Olsen

James White

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BOADDGDLSBDBGSX
Date   Source Headline
3rd Jun 20264:00 pmRNSHolding(s) in Company
2nd Jun 20267:02 amRNSDirectorate change
2nd Jun 20267:00 amRNSInterim results
1st Jun 20267:00 amRNSTotal Voting Rights
28th May 20262:36 pmRNSHolding(s) in Company
22nd May 20269:15 amRNSHolding(s) in Company
21st May 20267:00 amRNSHolding(s) in Company
14th May 20267:00 amRNSHolding(s) in Company
1st May 20267:00 amRNSHolding(s) in Company
1st May 20267:00 amRNSTotal Voting Rights
1st Apr 20267:00 amRNSTotal Voting Rights
31st Mar 20263:46 pmRNSDirector/PDMR Shareholding
19th Mar 202611:00 amRNSHolding(s) in Company
4th Mar 20267:00 amRNSAppointment of non-executive director
2nd Mar 20269:15 amRNSTotal Voting Rights
20th Feb 20262:48 pmRNSResult of AGM
20th Feb 20267:00 amRNSAGM Update
16th Feb 20267:00 amRNSHolding(s) in Company
9th Feb 20267:00 amRNSHolding(s) in Company
2nd Feb 20267:00 amRNSTotal Voting Rights
23rd Jan 20264:41 pmRNSDirector/PDMR Shareholding
12th Jan 20261:35 pmRNSNotice of AGM
2nd Jan 202610:29 amRNSTotal Voting Rights
19th Dec 202511:53 amRNSHolding(s) in Company
19th Dec 202511:53 amRNSHolding(s) in Company
18th Dec 20257:00 amRNSBlock listing Interim Review
16th Dec 20257:00 amRNSDirector/PDMR Shareholding
16th Dec 20257:00 amRNSDirector/PDMR Shareholding
16th Dec 20257:00 amRNSDirector/PDMR Shareholding
16th Dec 20257:00 amRNSDirector/PDMR Shareholding
16th Dec 20257:00 amRNSDirector/PDMR Shareholding
15th Dec 20258:42 amRNSTransaction in Own Shares
12th Dec 20257:00 amRNSTransaction in Own Shares
11th Dec 20253:01 pmRNSAdditional Listing - Replacement
11th Dec 20257:00 amRNSTransaction in Own Shares
10th Dec 202512:41 pmRNSDirector/PDMR Shareholding
10th Dec 202512:40 pmRNSDirector/PDMR Shareholding
10th Dec 202512:40 pmRNSDirector/PDMR Shareholding
10th Dec 202512:38 pmRNSDirector/PDMR Shareholding
10th Dec 202512:36 pmRNSDirector/PDMR Shareholding
10th Dec 202512:36 pmRNSDirector/PDMR Shareholding
10th Dec 20257:00 amRNSAdditional Listing
10th Dec 20257:00 amRNSTransaction in Own Shares
9th Dec 20254:23 pmRNSDirector/PDMR Shareholding
9th Dec 20257:00 amRNSResults for the year ended 31 October 2025
9th Dec 20257:00 amRNSTransaction in Own Shares
8th Dec 20257:00 amRNSTransaction in Own Shares
5th Dec 20257:00 amRNSTransaction in Own Shares
4th Dec 20257:00 amRNSTransaction in Own Shares
3rd Dec 20257:00 amRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.